LEA.135 expression: Its comparison with other prognostic biomarkers for patients with primary breast carcinoma

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1451-1461

  Liu, Dongxin ^a   Baltayan, Armine ^a   Naritoku, Wesley Y ^a   Barr, Nancy J ^a   Young, Lillian L ^a   Chaiwun, Benjaporn ^a   Tsao Wei, Denice D ^a   Groshen, Susan L ^a   Taylor, Clive R ^a   Torloni, Humberto ^b   Neville, A Munro ^c   Cote, Richard J ^a   Imam, S Ashraf ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Breast carcinoma; c erbB 2; Estrogen receptor; LEA. 135; MIB 1; Progesterone receptor; Prognosis; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; LEA 135; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME;

AGE FACTORS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033867352     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. The American Cancer Society. Cancer facts and figures, 1990, 1991 and 1992. Atlanta, GA: The American Cancer Society.
2. Adair F, Berg J, Joubert L, Robbins GF: Long-term follow-up of breast cancer patients. A 30-year report. Cancer 33: 1145-50, 1974.
3. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients w ith median follow-up of 18 years. J Clin Oncology 7: 1239-51, 1989.
4. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed 15 years. Br J Cancer 11: 359-77, 1957.
5. Nemoto T, Nana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917-24, 1980.
6. Pertschuk L, Kim DS, Nayel K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL: Immunohistochemical estrogen and progesterone receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlation and relationship to endocrine response and survival. Cancer 66: 1663-70, 1990.
7. Imam SA, Esteban EF, Young LL, Taylor CR: Generation of murine monoclonal antibody to normal mammary epithelium using mice rendered immune-tolerant to malignant mammary epithelium. J Histochem Cytochem 42: 585-91, 1994.
8. Imam SA, Pathak S, Brown N, Yilmaz A, Taylor CR: Development of tumorigenicity and rearrangement of chromosome 1 correlates with down-regulation of cell-surface glycoproteins in human mammary carcinoma cell line. Anticancer Res 14: 229-36, 1994.
9. Imam SA, Esteban EF, Chen RS, Cardiff RD, Taylor CR: Identification of a cell-surface antigen (LEA.135) associated with favorable prognosis in human breast cancer. Cancer Res 53: 3233-6, 1993.
10. Imam SA, Chaiwun B, Wang MJ, Morris MM, Groshen SG, Neville AM, Torloni H, Cote RJ, Taylor CR: A sialoglycoprotein (LEA.135) associated with favorable prognosis of patients with lymph node negative primary breast carcinoma. Anticancer Res 16: 3043-8, 1996.
11. Miller RG: Survival analysis. John Wiley & Sons, NY, 1981.
12. Tubiana M, Pejovic MJ, Renaud A, Contesso G, Chavaudra N, Gioanni J, Malaise EP: Kinetic parameters and the course ofthe disease in breast cancer. Cancer 47: 937-43, 1981.
13. Heck MMS, Earnshaw WC: Topoisomerase II α specific marker for cell proliferation. J Cell Biol 103: 2569-81, 1986.
14. Hellemans P, Van Dam PA, Geysken M, Van Oosterom AT, Buylaet P, Van Marker E: Immunohistochemical study of topoisomerase II-α expression in primary ductal carcinoma of the breast. J Clin Pathol 48: 147-50, 1995.
15. Jarvinen TAH, Kononen J, Pelto-Huikko M, Isola J: Expression of topoisomerase II α is associated with rapid cell proliferation, aneuploidy, and c-erbB-2 overexpression in breast cancer. Am J Pathol 148: 2073-82, 1996.
16. Haerslev T, Jacobsen GK: An immunohistochemical study of p53 with correlations to histopathological parameters, c-erhB-2, proliferating cell nuclear antigen, and prognosis. Human Pathol 26: 295-301, 1995.
17. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-10, 1991.
18. Horak ER, Harris AL, Stuart N, Bicknell R: Angiogenesis in breast cancer: Regulation, prognostic aspects and implications for novel treatment strategies. Ann N Y Acad Sci 698: 71-84, 1993.
19. Wynford-Thomas D: Oncogenes and anti-oncogenes: the molecular basis of tumor behavior. J Pathol 165: 187-201, 1991.
20. Hollingsworth RE, Lee WH: Tumor suppressor genes: new prospects for cancer research. J Natl Cancer Inst 83: 91-6, 1991.
21. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: P53 expression in breast cancer. Int J Cancer 41: 178-83, 1988.
22. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lelmard TJW, Anggus B, Horne CHW: P53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75-81, 1991.
23. Davidoff AM, Herndon JE, Glover NS, Kerns BJM, Pence JC, Iglehart JD, Marks JR: Relation between p53 over-expression and established prognostic factors in breast cancer. Surgery 110: 259-64, 1991.
24. Friedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and, prognosis in breast cancer. Cancer 72: 3641-7, 1993.
25. Elledge RM, Fugua SAW, Clark GM, Pujol P, Allred C: The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 27: 95-102, 1993.
26. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Prognostic value of p53 in breast invasive breast carcinomas: An immunohistochemical study on 942 cases. Breast Cancer Res Treat 36: 71-81, 1995.
27. Bieche I, Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 14: 227-51, 1995.
28. Bertheau P, Steinberg SM, Merino MJ: C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Human Pathol 29: 323-9, 1998.
29. Schecter AL, Stern DF, Vaidyanathan L, Deckel SJ: The neu oncogene: an erbB-related gene encoding a 185,000 Mr tumor antigen. Nature 312: 513-6, 1984.
30. Maguire HC Jr, Greene MI: The neu (c-erbB-2) oncogen. Semin Oncol 16: 148-55, 1989.
31. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448-52, 1988.
32. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-90, 1989.
33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-82, 1987.
34. Zhou DJ, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105-8, 1989.